According to the World Health Organization (WHO) emergence of antibiotic-resistant 'superbugs' is now a global concern, which can spell the end of modern medicine and a return to the days when routine operations, simple wounds or straightforward infections were potentially life-threatening.
On the other hand scientists have come to realize that the vast majority of bacteria is beneficial and should be left intact. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance.
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria - including antibiotic resistant strains such as MRSA - while leaving our microbiome - comprising billions of beneficial bacteria on our skin and in our gut - intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us: killing the bad bacteria and preserving the microbiome.
Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections (see www.gladskin.com).
A series of pharmaceutical products based on the endolysin XZ.700 - also targeting S. aureus - is in clinical development. First indications include: atopic dermatitis, diabetic wound infections and folliculitis.
Micreos has also developed FDA-approved food safety products: 'Phageguard S' against Salmonella and 'Phageguard L' against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised (www.phageguard.com).
On the other hand scientists have come to realize that the vast majority of bacteria is beneficial and should be left intact. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance.
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria - including antibiotic resistant strains such as MRSA - while leaving our microbiome - comprising billions of beneficial bacteria on our skin and in our gut - intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us: killing the bad bacteria and preserving the microbiome.
Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections (see www.gladskin.com).
A series of pharmaceutical products based on the endolysin XZ.700 - also targeting S. aureus - is in clinical development. First indications include: atopic dermatitis, diabetic wound infections and folliculitis.
Micreos has also developed FDA-approved food safety products: 'Phageguard S' against Salmonella and 'Phageguard L' against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised (www.phageguard.com).
Location: Netherlands, South Holland, The Hague
Employees: 51-200
Total raised: $111.56M
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | Oost NL | oostnl.com |
| - | ScaleUpNat... | scaleupnat... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 26.10.2022 | - | $24.65M | Venture Ki... |
| 30.09.2021 | - | $37.1M | - |
| 12.11.2019 | - | $2.75M | - |
| 29.03.2019 | - | $33.71M | - |
| 18.02.2016 | - | $13.36M | - |
Mentions in press and media 11
| Date | Title | Description |
| 30.12.2022 | Dutch-based biotech and life sciences startups that raised funding in 2022 | The Netherlands is swiftly rising to the top as a hub for healthcare and life sciences innovation. More and more Dutch startups are engaged in a range of cutting-edge initiatives, such as the creation of digital health tools, the developmen... |
| 28.10.2022 | Dutch-Swiss biotech firm Micreos bags €25M to develop alternatives to antibiotics | The Hague-based Micreos, a Dutch/Swiss biotech company, announced on Tuesday, October 25, that it has secured €25M in growth funding in a fresh round. The company will use the funds to invest in its specialised skincare brand, Gladskin, for... |
| 25.10.2022 | Micreos Secures €25M in Growth Funding | Micreos, a Dutch/Swiss biotech company, raised €25M in Growth funding. The backers were not disclosed. Led by CEO Mark Offerhaus, Micreos develops targeted antibacterial solutions based on endolysin and phage technology as a sustainable alt... |
| 05.10.2021 | Dutch biotech startup Micreos secures €32M as it plans to replace antibiotics; here’s how | Netherlands-based biotechnology company Micreos announced that it has raised €32M in a fresh round of funding. The company had raised €30M in March 2019 and, also in the same year, was awarded the highest possible sum of €2.5M under the EU’... |
| 01.10.2021 | Micreos lands $37M to show whether antibiotic alternative delivers in the clinic | Investors have bought into Micreos’ vision for a sustainable alternative to antibiotics. With backers putting up 32 million euros ($37 million), Micreos is now poised to show whether its platform can generate more targeted, harder-to-resist... |
| 01.10.2021 | Micreos lands $37M to show whether antibiotic alternative delivers in the clinic | Investors have bought into Micreos’ vision for a sustainable alternative to antibiotics. With backers putting up 32 million euros ($37 million), Micreos is now poised to show whether its platform can generate more targeted, harder-to-resist... |
| 30.09.2021 | Micreos Raises €32M in Funding | Micreos, a The Hague, The Netherlands-based biotechnology company, secured another €32m in funding. The company intends to use the funds to accelerate clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstre... |
| 18.12.2020 | Gladskin’s President Skyler Stein Talks Endolysin Technology – Q/A | Skyler Stein, President of Gladskin We recently spoke with Skyler Stein, President of Dutch biotechnology company Gladskin to learn more about its global endolysin technology that uses its science to improve inflammatory skin conditions by ... |
| 05.11.2018 | Micreos Establishes South African Collaboration to Combat Listeria, Salmonella and e-Coli | At the end of February, Oost NL organized an acquisition trade mission of South African companies. Among the participants in this mission was the Dutch biotechnology company Micreos. Introductions were facilitated by Oost NL between Micreos... |
| 18.02.2016 | Micreos Secures €12M in Equity Funding | Micreos, a Wageningen, Netherlands-based biotech company, secured €12m in equity funding. The backers remained undisclosed. The company will use the funds for the global development of Staphefekt™, its antibacterial lysin technology, as a p... |
Show more